Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice
Antibodies are considered as ‘magic bullets’ because of their high specificity. It is believed that antibodies are too large to routinely enter the cytosol, thus antibody therapeutic approach has been limited to extracellular or secreted proteins expressed by cancer cells. However, many oncogenic pr...
Saved in:
Main Authors: | Guo, Ke, Tang, Jing Ping, Jie, Li, Hong, Cheng William, Tan, Cheng Peow Bobby, Park, Jung Eun, Varghese, Leyon, Feng, Zhiwei, Zhou, Jianbiao, Chng, Wee Joo, Zeng, Qi, Al-Aidaroos, Abdul Qader O. |
---|---|
Other Authors: | School of Biological Sciences |
Format: | Article |
Language: | English |
Published: |
2013
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/98490 http://hdl.handle.net/10220/10924 http://www.ncbi.nlm.nih.gov.ezlibproxy1.ntu.edu.sg/pmc/articles/PMC3326646/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice
by: Guo, Ke, et al.
Published: (2021) -
Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice
by: Guo, K., et al.
Published: (2014) -
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
by: Thura, Min, et al.
Published: (2019) -
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (vol 10, 2484, 2019)
by: Thura, Min, et al.
Published: (2021) -
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
by: Thura M., et al.
Published: (2020)